RCN Pareto Strategic Allocation ETF (NYSEARCA:PRTO) Stock Short Interest Report for October

RCN Pareto Strategic Allocation ETF (NYSEARCA:PRTO) was the target of a significant decrease in short interest during the month of October. As of October 15th, there was short interest totaling 425 shares, a decrease of 38.5% from the September 30th total of 691 shares. Currently, 0.1% of the shares of the company are sold short. Based on an average daily volume of 257 shares, the days-to-cover ratio is presently 1.7 days.

RCN Pareto Strategic Allocation ETF Price Performance

Shares of NYSEARCA:PRTO opened at $26.93 on Friday. The company has a market capitalization of $17.24 million, a price-to-earnings ratio of -28.05 and a beta of -1.05. RCN Pareto Strategic Allocation ETF has a twelve month low of $24.68 and a twelve month high of $28.58. The stock’s 50-day simple moving average is $27.56.

Proteon Therapeutics was a biopharmaceutical company focused on developing treatments for patients with kidney and vascular diseases. The company’s research and development efforts centered on therapies designed to address severe and life-threatening conditions, particularly those related to renal disease and vascular access for hemodialysis patients.

One of Proteon Therapeutics’ best-known product candidates was vonapanitase, an investigational enzyme developed to improve vascular access outcomes in patients with end-stage renal disease who require hemodialysis.